Albumin infusion may decrease the mortality of hypoalbuminemia patients with severe acute pancreatitis: a retrospective cohort study.
Albumin infusion
Hypoalbuminemia
Mortality
Prognosis
Severe acute pancreatitis
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
05 Jun 2023
05 Jun 2023
Historique:
received:
02
10
2022
accepted:
04
05
2023
medline:
7
6
2023
pubmed:
6
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
At present, the relationship between severe acute pancreatitis (SAP) and albumin infusion is not clear. We aimed to identify the impact of serum albumin on the prognosis of SAP and the association between albumin infusions and mortality for hypoalbuminemia patients. This was a retrospective cohort study that analyzed 1000 patients with SAP who were admitted to the First Affiliated Hospital of Nanchang University between January 2010 and December 2021 using data from a prospectively maintained database. Multivariate logistic regression analysis was conducted to reveal the relationship between serum albumin within 1 week after admission and poor prognosis of SAP. Propensity score matching (PSM) analysis was adopted to evaluate the effect of albumin infusion for hypoalbuminemia patients with SAP. The prevalence of hypoalbuminemia (≤ 30 g/L) was 56.9% within 1 week after admission. Multivariate logistic regression identified that age (OR: 1.02; 95% CI: 1.00-1.04; P = 0.012), serum urea (OR: 1.08; 95% CI: 1.04-1.12; P < 0.001), serum calcium (OR: 0.27; 95% CI: 0.14-0.50; P < 0.001), lowest albumin level within 1 week after admission (OR: 0.93; 95% CI: 0.89-0.97; P = 0.002), and APACHE II score ≥ 15 (OR: 1.73; 95% CI: 1.19-2.51; P = 0.004) were independently associated with mortality. The PSM analysis demonstrated that mortality (OR: 0.52, 95% CI: 0.29-0.92, P = 0.023) was less common in albumin-infused than non-albumin-infused hypoalbuminemia patients. In subgroup analyses, doses > 100 g within 1 week after admission for hypoalbuminemia patients with albumin infusions was associated with lower mortality than doses ≤ 100 g (OR: 0.51, 95% CI: 0.28-0.90, P = 0.020). Hypoalbuminemia in early-stage SAP is significantly related to poor prognosis. However, albumin infusions could significantly decrease mortality in hypoalbuminemia patients with SAP. Additionally, infusing sufficient albumin within a week after admission may decrease mortality in hypoalbuminemia patients.
Sections du résumé
BACKGROUND
BACKGROUND
At present, the relationship between severe acute pancreatitis (SAP) and albumin infusion is not clear. We aimed to identify the impact of serum albumin on the prognosis of SAP and the association between albumin infusions and mortality for hypoalbuminemia patients.
METHODS
METHODS
This was a retrospective cohort study that analyzed 1000 patients with SAP who were admitted to the First Affiliated Hospital of Nanchang University between January 2010 and December 2021 using data from a prospectively maintained database. Multivariate logistic regression analysis was conducted to reveal the relationship between serum albumin within 1 week after admission and poor prognosis of SAP. Propensity score matching (PSM) analysis was adopted to evaluate the effect of albumin infusion for hypoalbuminemia patients with SAP.
RESULTS
RESULTS
The prevalence of hypoalbuminemia (≤ 30 g/L) was 56.9% within 1 week after admission. Multivariate logistic regression identified that age (OR: 1.02; 95% CI: 1.00-1.04; P = 0.012), serum urea (OR: 1.08; 95% CI: 1.04-1.12; P < 0.001), serum calcium (OR: 0.27; 95% CI: 0.14-0.50; P < 0.001), lowest albumin level within 1 week after admission (OR: 0.93; 95% CI: 0.89-0.97; P = 0.002), and APACHE II score ≥ 15 (OR: 1.73; 95% CI: 1.19-2.51; P = 0.004) were independently associated with mortality. The PSM analysis demonstrated that mortality (OR: 0.52, 95% CI: 0.29-0.92, P = 0.023) was less common in albumin-infused than non-albumin-infused hypoalbuminemia patients. In subgroup analyses, doses > 100 g within 1 week after admission for hypoalbuminemia patients with albumin infusions was associated with lower mortality than doses ≤ 100 g (OR: 0.51, 95% CI: 0.28-0.90, P = 0.020).
CONCLUSIONS
CONCLUSIONS
Hypoalbuminemia in early-stage SAP is significantly related to poor prognosis. However, albumin infusions could significantly decrease mortality in hypoalbuminemia patients with SAP. Additionally, infusing sufficient albumin within a week after admission may decrease mortality in hypoalbuminemia patients.
Identifiants
pubmed: 37277756
doi: 10.1186/s12876-023-02801-8
pii: 10.1186/s12876-023-02801-8
pmc: PMC10243000
doi:
Substances chimiques
Serum Albumin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
195Subventions
Organisme : National Natural Science Foundation of China
ID : 82100686
Organisme : National Natural Science Foundation of China
ID : 81760121
Organisme : the Jiangxi Provincial Natural Science Foundation
ID : 20212BAB216015
Organisme : the Jiangxi Provincial Natural Science Foundation
ID : 20202BAB206010
Organisme : the Youth Talent Project of the First Affiliated Hospital of Nanchang University
ID : YFYPY202006
Organisme : Funding Scheme for Outstanding Young Talent in Jiangxi Province
ID : 20192BCB23021
Informations de copyright
© 2023. The Author(s).
Références
N Engl J Med. 2004 May 27;350(22):2247-56
pubmed: 15163774
Pancreas. 2013 May;42(4):633-9
pubmed: 23303203
N Engl J Med. 2014 Apr 10;370(15):1412-21
pubmed: 24635772
Clin Nutr. 1999 Aug;18(4):197-201
pubmed: 10578018
JAMA. 1994 Oct 5;272(13):1036-42
pubmed: 8089886
Front Surg. 2023 Jan 10;9:1026604
pubmed: 36704518
Crit Care. 2014 Dec 15;18(6):702
pubmed: 25499187
Crit Care Med. 2006 Oct;34(10):2536-40
pubmed: 16915107
J Gastroenterol. 2008;43(2):152-8
pubmed: 18306989
Lancet. 2020 Sep 5;396(10252):726-734
pubmed: 32891214
Sci Rep. 2021 Dec 21;11(1):24379
pubmed: 34934165
Gastroenterology. 2018 Mar;154(4):1096-1101
pubmed: 29409760
Intensive Care Med. 2006 Nov;32(11):1722-32
pubmed: 16967294
Am J Gastroenterol. 2015 Dec;110(12):1707-16
pubmed: 26553208
Gastroenterology. 2019 Jul;157(1):149-162
pubmed: 30905652
BMC Gastroenterol. 2017 Apr 26;17(1):59
pubmed: 28446147
Gut. 2013 Jan;62(1):102-11
pubmed: 23100216
Lancet. 2018 Jun 16;391(10138):2417-2429
pubmed: 29861076
Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):479-496
pubmed: 31138897
JAMA. 2021 Jan 26;325(4):382-390
pubmed: 33496779
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015 Jun;27(6):401-26
pubmed: 26049176
J Crit Care. 2019 Apr;50:144-154
pubmed: 30540968
Intern Emerg Med. 2012 Oct;7 Suppl 3:S193-9
pubmed: 23073857
Sci Rep. 2021 Dec 17;11(1):24158
pubmed: 34921151
Clin Nutr. 2001 Jun;20(3):265-9
pubmed: 11407875
Chin Med J (Engl). 2021 Jul 20;134(14):1639-1654
pubmed: 34397592
Lancet. 2015 Jul 4;386(9988):85-96
pubmed: 25616312
Nutr J. 2019 Jun 28;18(1):33
pubmed: 31253199
Cochrane Database Syst Rev. 2018 Aug 03;8:CD000567
pubmed: 30073665
Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416
pubmed: 23896955
Intensive Care Med. 2010 Oct;36(10):1657-1665
pubmed: 20517593
Gastroenterology. 2009 Jul;137(1):129-35
pubmed: 19344722
Cureus. 2022 Sep 16;14(9):e29243
pubmed: 36262941
Crit Care. 2014 Jul 16;18(4):231
pubmed: 25042164
Biol Res Nurs. 2019 May;21(3):237-244
pubmed: 30722677
Crit Care Med. 2021 Nov 1;49(11):e1063-e1143
pubmed: 34605781
Hepatobiliary Pancreat Dis Int. 2017 Aug 15;16(4):424-430
pubmed: 28823374
J Antimicrob Chemother. 1998 Jan;41 Suppl A:51-63
pubmed: 9511087
Am J Gastroenterol. 2010 Feb;105(2):435-41; quiz 442
pubmed: 19861954
BMC Surg. 2020 Dec 9;20(1):322
pubmed: 33298030
Postepy Hig Med Dosw (Online). 2016 Apr 13;70:305-12
pubmed: 27117106
Can J Gastroenterol Hepatol. 2017;2017:5297143
pubmed: 29147647
BMJ. 2019 Dec 2;367:l6227
pubmed: 31791953
Front Pharmacol. 2021 Dec 14;12:772975
pubmed: 34970144
Gastroenterology. 1960 May;38:769-76
pubmed: 14406821
Gut. 2008 Dec;57(12):1698-703
pubmed: 18519429